Urteste S.A.
1 Starodworska Street
80-137 Gdańsk

June 23, 2025.

Current report number
6/2025 dated June 23, 2025.

Subject: Completion of development work and achievement of technological readiness to start performance evaluation (clinical trial) in the Panuri project

Legal posture: Article 17(1) MAR - confidential information.

The Management Board of Urteste S.A. ("Issuer", "Company") announces that on June 23, 2025, it accepted the report on the development work of a test for detecting pancreatic cancer from a urine sample (Panuri project). As part of the development work, the functional parameters of the Panuri test were confirmed.

As a result of the R&D work carried out over the past few quarters, the components included in the Panuri test kit were developed: reagent buffer, reagents, incubation buffer and Panuri control positive control.

In addition, in the course of development, an in-process control was also carried out and the pre-analytical phase of the test was optimized.

The performance of the in-process control enabled:

- full quality control, using identified reactants of the highest purity;
- selection of the optimal concentration of reagents;
- repeatability of results;

and ensures compliance with IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices - In Vitro Diagnostic Regulation).

Optimization of the pre-analytical phase has enabled:

- Elimination of interference from other sample components;
- control of transport time and conditions - maintaining enzymatic activity;
- reducing the risk of random errors and eliminating systematic errors. As a result

of the work carried out:

- high-quality reagents were obtained;
- the structure and purity of the reagents were confirmed;
- the reproducibility and efficiency of the diagnostic test was ensured, the results are statistically significant

significant;

- the number of false results (both positive and negative) was reduced;

- The process of reading the results has been automated.

Taking into account the stringent regulatory requirements of the European and U.S. markets, the following assumptions were made for the design of the performance test (clinical trial) resulting from the above-mentioned R&D work completed:

- Sensitivity - 89%,
- Specificity - 75%,
- Diagnostic accuracy - 81%.

Research at the development stage was conducted on a statistically representative group of participants.

The very high repeatability of measurements was also confirmed. The level of the index of of precision (CV) for the Tecan Fluent diagnostic device used was <1%.

The Company's Management Board positively evaluates the results contained in the report on the completed development work
and on this basis decided to continue the project.

The Company plans to start the performance study (clinical trial) in the third quarter of 2025.

The Company will report on further significant developments in the Panuri project, including the commencement of the efficacy study (clinical trial), in the form of separate reports.